Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

Anne H. Cross; Jennifer L. Stark; Joanne Lauber; Michael J. Ramsbottom; Jeri Anne Lyons

doi:10.1016/j.jneuroim.2006.06.029

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

Anne H. Cross, Jennifer L. Stark, Joanne Lauber, Michael J. Ramsbottom, Jeri Anne Lyons

Research output: Contribution to journal › Article › peer-review

384 Scopus citations

Abstract

Effects of B cell depletion by rituximab, a monoclonal antibody to CD20, were studied in patients with relapsing MS that had not responded optimally to standard immunomodulatory therapies. Flow cytometry demonstrated reduced cerebrospinal fluid (CSF) B cells and T cells in most patients at 6 months post-treatment. ELISAs demonstrated modest reductions in serum antibodies to myelin oligodendrocyte glycoprotein and myelin basic protein in some subjects. Beta-interferon neutralizing antibodies were reduced in three subjects, but developed anew after treatment in three others, suggesting caution in considering rituximab as a means to eliminate NABs. In summary, rituximab depleted B cells from CSF at 24 weeks after initial treatment, and this B cell depletion was associated with a reduction in CSF T cells as well.

Original language	English
Pages (from-to)	63-70
Number of pages	8
Journal	Journal of Neuroimmunology
Volume	180
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jneuroim.2006.06.029
State	Published - Nov 2006

Keywords

Autoantibodies
B lymphocytes
Multiple sclerosis
Myelin basic protein antibodies
Myelin oligodendrocyte glycoprotein antibodies
Rituximab
Treatment

Access to Document

10.1016/j.jneuroim.2006.06.029

Cite this

@article{f433e96d32914405aa0d9c2ca1b955ee,

title = "Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients",

abstract = "Effects of B cell depletion by rituximab, a monoclonal antibody to CD20, were studied in patients with relapsing MS that had not responded optimally to standard immunomodulatory therapies. Flow cytometry demonstrated reduced cerebrospinal fluid (CSF) B cells and T cells in most patients at 6 months post-treatment. ELISAs demonstrated modest reductions in serum antibodies to myelin oligodendrocyte glycoprotein and myelin basic protein in some subjects. Beta-interferon neutralizing antibodies were reduced in three subjects, but developed anew after treatment in three others, suggesting caution in considering rituximab as a means to eliminate NABs. In summary, rituximab depleted B cells from CSF at 24 weeks after initial treatment, and this B cell depletion was associated with a reduction in CSF T cells as well.",

keywords = "Autoantibodies, B lymphocytes, Multiple sclerosis, Myelin basic protein antibodies, Myelin oligodendrocyte glycoprotein antibodies, Rituximab, Treatment",

author = "Cross, {Anne H.} and Stark, {Jennifer L.} and Joanne Lauber and Ramsbottom, {Michael J.} and Lyons, {Jeri Anne}",

note = "Funding Information: Supported by the National Multiple Sclerosis Society USA RG 3292; NIH K24RR017100-02; the Washington University General Clinical Research Center MO1 RR00036; Genentech/IDEC. Dr. Cross was supported in part by the Manny and Rosalyn Rosenthal–Dr. John L. Trotter Chair in Neuroimmunology. We thank Robert Mikesell for excellent technical assistance, Drs. Becky Jo Parks and Robert T. Naismith for referral of patients and our patients for their participation. The paper is dedicated to the memory of this MS Center's founder, Dr. John L. Trotter (1943–2001).",

year = "2006",

month = nov,

doi = "10.1016/j.jneuroim.2006.06.029",

language = "English",

volume = "180",

pages = "63--70",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

number = "1-2",

}

TY - JOUR

T1 - Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

AU - Cross, Anne H.

AU - Stark, Jennifer L.

AU - Lauber, Joanne

AU - Ramsbottom, Michael J.

AU - Lyons, Jeri Anne

N1 - Funding Information: Supported by the National Multiple Sclerosis Society USA RG 3292; NIH K24RR017100-02; the Washington University General Clinical Research Center MO1 RR00036; Genentech/IDEC. Dr. Cross was supported in part by the Manny and Rosalyn Rosenthal–Dr. John L. Trotter Chair in Neuroimmunology. We thank Robert Mikesell for excellent technical assistance, Drs. Becky Jo Parks and Robert T. Naismith for referral of patients and our patients for their participation. The paper is dedicated to the memory of this MS Center's founder, Dr. John L. Trotter (1943–2001).

PY - 2006/11

Y1 - 2006/11

N2 - Effects of B cell depletion by rituximab, a monoclonal antibody to CD20, were studied in patients with relapsing MS that had not responded optimally to standard immunomodulatory therapies. Flow cytometry demonstrated reduced cerebrospinal fluid (CSF) B cells and T cells in most patients at 6 months post-treatment. ELISAs demonstrated modest reductions in serum antibodies to myelin oligodendrocyte glycoprotein and myelin basic protein in some subjects. Beta-interferon neutralizing antibodies were reduced in three subjects, but developed anew after treatment in three others, suggesting caution in considering rituximab as a means to eliminate NABs. In summary, rituximab depleted B cells from CSF at 24 weeks after initial treatment, and this B cell depletion was associated with a reduction in CSF T cells as well.

AB - Effects of B cell depletion by rituximab, a monoclonal antibody to CD20, were studied in patients with relapsing MS that had not responded optimally to standard immunomodulatory therapies. Flow cytometry demonstrated reduced cerebrospinal fluid (CSF) B cells and T cells in most patients at 6 months post-treatment. ELISAs demonstrated modest reductions in serum antibodies to myelin oligodendrocyte glycoprotein and myelin basic protein in some subjects. Beta-interferon neutralizing antibodies were reduced in three subjects, but developed anew after treatment in three others, suggesting caution in considering rituximab as a means to eliminate NABs. In summary, rituximab depleted B cells from CSF at 24 weeks after initial treatment, and this B cell depletion was associated with a reduction in CSF T cells as well.

KW - Autoantibodies

KW - B lymphocytes

KW - Multiple sclerosis

KW - Myelin basic protein antibodies

KW - Myelin oligodendrocyte glycoprotein antibodies

KW - Rituximab

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=33751085414&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2006.06.029

DO - 10.1016/j.jneuroim.2006.06.029

M3 - Article

C2 - 16904756

AN - SCOPUS:33751085414

SN - 0165-5728

VL - 180

SP - 63

EP - 70

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

IS - 1-2

ER -

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this